Hospital
Springhill Medical Services, INC.
Springhill Medical Services, INC. was paid $4.05M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99284, emergency room visit (serious) — 42% of everything it billed.
33Billing provider infoSPRINGHILL MEDICAL SERVICES, INC.
SPRINGHILL, LA 71075
SPRINGHILL, LA 71075
33aNPI1275506115assigned 02/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.05M
24GClaims97,652
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#55 of 96
Median peer was paid$5.17M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,758 | $347K | |
| 2019 | 14,471 | $423K | |
| 2020 | 11,112 | $411K | |
| 2021 | 16,305 | $726K | |
| 2022 | 16,334 | $735K | |
| 2023 | 15,456 | $814K | |
| 2024incomplete | 11,216 | $595K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 42% | 4,509 | 4,012 | $1.68M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 36% | 7,719 | 7,052 | $1.44M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.0% | 3,888 | 3,514 | $122K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 166 | 152 | $99K |
| G0378 | Hospital observation service, per hour | 1.9% | 69 | 49 | $77K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 975 | 929 | $68K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 11,933 | 10,200 | $64K |
| 80050 | General health panel | 1.5% | 1,474 | 1,381 | $62K |
| 80053 | Comprehensive metabolic panel | 1.5% | 7,953 | 6,921 | $60K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 24,150 | 20,656 | $51K |
| 80061 | Lipid panel | 1.1% | 3,834 | 3,587 | $44K |
| 0240U | <1% | 293 | 242 | $33K |
63 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 288 | $31K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,823 | $23K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 784 | $21K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 49 | $15K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 781 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 259 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,367 | $11K |
| 71045 | Radiologic examination, chest; single view | <1% | 183 | $10K |
| 84439 | <1% | 1,015 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 882 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 398 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 330 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 375 | $7K |
| 81001 | <1% | 2,744 | $6K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 58 | $6K |
| 87400 | <1% | 514 | $5K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 85 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 92 | $4K |
| 87428 | <1% | 190 | $4K | |
| 93041 | <1% | 76 | $3K | |
| 87430 | <1% | 248 | $3K | |
| 0011A | <1% | 175 | $3K | |
| 0012A | <1% | 89 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 50 | $3K |
| 87070 | <1% | 284 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 125 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 78 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 181 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 23 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 51 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 51 | $2K |
| 83735 | <1% | 333 | $2K | |
| 81025 | <1% | 174 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 222 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 104 | $1K |
| Q3014 | Telehealth originating site facility fee | <1% | 362 | $1K |
| 83880 | <1% | 42 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 625 | $957.13 |
| 80074 | <1% | 17 | $666.82 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 28 | $601.76 |
| 84484 | <1% | 63 | $511.27 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 20 | $481.60 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17 | $376.90 |
| A9270 | Non-covered item or service | <1% | 12,852 | $304.66 |
| J2704 | Injection, propofol, 10 mg | <1% | 693 | $270.37 |
| 82607 | <1% | 13 | $196.04 | |
| 82746 | <1% | 13 | $191.10 | |
| 84481 | <1% | 13 | $174.59 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 18 | $132.66 |
| 87807 | <1% | 13 | $131.00 | |
| J3490 | Unclassified drugs | <1% | 974 | $101.15 |
| 86592 | <1% | 20 | $85.40 | |
| 87077 | <1% | 52 | $77.87 | |
| 83690 | <1% | 14 | $68.90 | |
| 87186 | <1% | 12 | $64.02 | |
| 87210 | <1% | 24 | $63.91 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19 | $62.80 |
| 82570 | <1% | 12 | $62.16 | |
| 82043 | <1% | 12 | $52.02 | |
| 82044 | <1% | 12 | $49.68 | |
| C9399 | Unclassified drugs or biologicals | <1% | 25 | $0.90 |
| 91301 | <1% | 189 | $0.02 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 54 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPATRONIS, MICHAEL (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Springhill Medical Services, INC. | Springhill, LA | $11.73M |
| Springhill Medical Services, INC. | Sarepta, LA | $2.71M |
| Springhill Medical Services, INC. | Homer, LA | $1.84M |
| Springhill Medical Services, INC. | Springhill, LA | $129K |
| Springhill Medical Services, INC. | Bradley, AR | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.